MRNA
Moderna
Data as of 2026-07-21
Company attributes
Price
Interactive 5-year price history chart for MRNA. Latest close $59.66.
Pillar breakdown
0–100 percentile rank against the current universe (sector-relative for Quality / Value / Growth / Profitability)
- QualityProfit margins & asset efficiency7PoorHealth Care median (n=166) 50
- ValuePrice vs fundamentals51AverageHealth Care median (n=166) 52
- GrowthRevenue & earnings trajectory38WeakHealth Care median (n=166) 50
- MomentumRecent price strength70ExceptionalHealth Care median (n=166) 49
- HealthBalance sheet & solvency73ExceptionalHealth Care median (n=166) 57
- ProfitabilityROE, ROA, ROIC4PoorHealth Care median (n=166) 48
- TechnicalTrend & volatility signals45AverageHealth Care median (n=166) 56
- RiskVolatility & drawdown profile31WeakHealth Care median (n=166) 46
Pillars not shown: Sentiment, ML (Phase 5+).
Risk Summary
1 active- Data-quality guard[data_quality_input_corruption]Upstream input out of range (e.g. share-count units) — fair-price methods suppressed (Step 7.5 sanity guard).
These flags keep the raw composite rank (project Rule 16) but forfeit the entered_top5 badge. Two of them — altman_distress and data_quality_input_corruption — additionally force a cautious recommendation; the others act as Top-5 disqualifiers without dictating the buy/hold/sell label on their own.
Fair price check
1 different valuation methods each estimate what MRNAshould be worth, then we compare to today's price.
- P/B multiplesUndervaluedthinks it's a bargain — estimates $98.65, about 65% above today
How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.
Fair price ensemble
- Median fair
- —
- Margin of safety(vs fair value)
- +39.5%
- Max (ex-outliers)
- —
- Tangible BVPS
- $18.25
- Valuation output anomalous
Median of all applicable methods (current price $59.66). Per-method estimates + each method’s cheap/fair/pricey read are in the Fair price check above. Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.
Defense layer. Flags mark elevated risk, never confirmed fraud. This model cannot catch every manipulation and decays after publication — weigh it against its stated error rates.
Supporting dataRaw fundamentals & data-quality provenance behind the scores above
Raw fundamentals (SEC EDGAR)
| Metric | Value |
|---|---|
| Market cap | $23.67B |
| Revenue (TTM) | $2.23B |
| Net income (TTM) | $-3.19B |
| Operating cash flow (TTM) | $88.00M |
| CapEx (TTM) | $137.00M |
| Free cash flow (TTM)CFO − CapEx | $-49.00M |
| Total assets | $11.49B |
| Total liabilities | $4.08B |
| Stockholders' equity | $7.41B |
| Cash & equivalents | $1.91B |
| Shares outstanding | 396.79M |
| EPS (basic) | $-8.05 |
| EPS (diluted) | $-8.05 |
| P/E ratio (TTM) | N/A |
TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).
Data quality
- Latest filed date
- 2026-05-01
- Latest period end
- 2026-04-24
- Filing lag
- 81 days
- Missing metrics
- 4(gross_profit, interest_expense, dividends_paid, short_term_debt)
Composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars are reserved for a later phase; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.